The disorder is considered orphan indication, and there are very limited
treatment options available in the market. However, several therapeutics
for Dravet syndrome are in pipeline. The drugs in development are
getting orphan drug designation by FDA and EMA.

The Dravet syndrome market in Europe and the U.S. is likely to exhibit
significant growth in the next five years due to increasing research and
development activities conducted by several companies. Several companies
are making alliances for developing therapeutics for Dravet syndrome.

Currently, the U.S. and Europe are holding the potential growth for
Dravet Syndrome market due to increasing R&D into new drug development
for Dravet syndrome and approval for these drugs in these regions.

Key players of the market include Zogenix, Zynerba, GW Pharmaceuticals,
and OPKO. Currently, only GW Pharmaceuticals' Epidiolex is commercially
available.

Other players are currently developing their drugs or seeking for
commercial approval by FDA and EMA. Zogenix's ZX008 is expected to
penetrate market in 2019 and create competition for GW Pharmaceuticals.
Currently, the market is dominated by generic drugs.

Dravet Syndrome

Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy
(SMEI), is a severe kind of epilepsy which causes seizures. High fever
is usually a trigger for these seizures. It is a rare disorder that
affects an estimated 1 in every 20,000-40,000 births.

It usually develops in the sixth month of age. It is caused by
loss-of-function mutations in one copy of the SCN1A gene. Patients with
Dravet syndrome are not able to produce sufficient levels of functional
Nav1.1 sodium channel, preventing inhibitory neurons from firing
properly.

Topics Covered

1. Overview

1.1 Dravet Syndrome

2. Global Dravet Syndrome Drug Market

2.1 ZX008 Sales Value Forecast

2.2 Epidiolex Sales Value Forecast

3. Regional Dravet Syndrome Drug Market

3.1 The U.S.

3.1.1 The U.S. Dravet Syndrome Patient Volume Forecast

3.1.2 ZX008 Sales Value Forecast in the U.S. Dravet Syndrome Market

3.1.3 Treated Dravet Syndrome Patients with ZX008 in the U.S. Forecast